3-氰基吡啶-5-硼酸频哪醇酯 | 402718-29-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氰基吡啶-5-硼酸频哪醇酯
• 中文别名: 5-(4,4,5,5-四甲基-[1,3,2]二氧硼烷)烟腈
• 英文名称: 3-cyanopyridine-5-boronic acid pinacol ester
• 英文别名: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile；5-cyanopyridi n-3-ylboronic acid pinacol ester；5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carbonitrile；5-cyanopyridine-3-boronic acid pinacol ester
• CAS: 402718-29-0
• 化学式: C₁₂H₁₅BN₂O₂
• 分子量: 230.074
• InChiKey: BOIKCRIMIQAFQJ-UHFFFAOYSA-N

物化性质

• 熔点：
  122-124℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.25
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Cyanopyridine-5-boronic acid pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Cyanopyridine-5-boronic acid pinacol ester
CAS number: 402718-29-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H15BN2O2
Molecular weight: 230.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氰基吡啶-5-硼酸频哪醇酯 在 hydrazine hydrate 、 caesium carbonate 作用下， 以 水 为溶剂， 反应 16.0h， 以85%的产率得到3-氰基-5-羟基吡啶
  参考文献：
  名称：

  一种催化氧化芳硼类化合物制备酚的方法

  摘要：

  本发明公开了一种催化氧化芳硼类化合物合成酚类化合物的方法，在溶剂醇或醇的水溶液中，在碱的作用下，加入水合肼或肼类化合物催化剂，催化氧化芳硼类化合物直接制备酚类化合物。本发明的制备酚类化合物的方法，催化剂是廉价的水合肼或肼类化合物，氧化剂为常压下的空气或氧气，反应无需金属催化剂且活性好，底物来源广泛且稳定，底物敏感官能团相容性好且适用范围广。在优化的反应条件之下，目标产品分离收率高达99%。

  公开号：

  CN103936538B
• 作为产物：
  描述：

  3-氰基吡啶 、 联硼酸频那醇酯 在 2,6-二叔丁基吡啶 、 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 3-氰基吡啶-5-硼酸频哪醇酯
  参考文献：
  名称：

  从Ag到Pd的两种配体转移：在途中（SIPr）Pd（CF2H）（X）的转移及其在一锅CH硼化/二氟甲基化中的应用。

  摘要：

  NHC配体和二氟甲基基团从[（SIPr）Ag（CF2H）]同时转移到PdX2（X = Cl，OAc和OPiv）的过程，用于制备[（SIPr）Pd（CF2H）X描述复合物。这些络合物是空气稳定的，易于通过芳基频哪醇硼酸酯/还原消除进行重金属化，从而以高收率生成ArCF2H。基于这一发现，开发了用于制备二氟甲基化（杂）芳烃的第一个单锅CH硼化和二氟甲基化方法。

  DOI：

  10.1021/acs.joc.9b03296

文献信息

• [EN] SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO<br/>[FR] COMPOSÉS PYRAZOLE ET PYRROLE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CES DERNIERS POUR L'INHIBITION DE L'INITIATION DE LA TRADUCTION ET LE TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS À CETTE DERNIÈRE
  申请人：BANTAM PHARMACEUTICAL LLC

  公开号：WO2016196644A1

  公开（公告）日：2016-12-08

  Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and /V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by "a", R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the elF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

  揭示了吡唑化合物，以及其药物组合物和使用方法。其中一种实施例是具有结构（I）及其药用可接受的盐和/或氧化物，其中X1、X2、Z1、Z2、由“a”表示的环系统、R1、A1A、L1B、A1B、L1A、L2、Q、L3、R3、A4A、L4B、A4B、L4A、R4、L5和R5如本文所述。在某些实施例中，本文所披露的化合物破坏elF4E/eiF4G相互作用，并可用于治疗过度增殖性疾病、神经系统疾病或障碍，或自闭症。
• Fragment-to-Hit-to-Lead Discovery of a Novel Pyridylurea Scaffold of ATP Competitive Dual Targeting Type II Topoisomerase Inhibiting Antibacterial Agents
  作者：Gregory S. Basarab、John I. Manchester、Shanta Bist、P. Ann Boriack-Sjodin、Brian Dangel、Ruth Illingworth、Brian A. Sherer、Shubha Sriram、Maria Uria-Nickelsen、Ann E. Eakin

  DOI：10.1021/jm401208b

  日期：2013.11.14

  The discovery and optimization of a new class of bacterial topoisomerase (DNA gyrase and topoisomerase IV) inhibitors binding in the ATP domain are described. A fragment molecule, 1-ethyl-3-(2-pyridyl)urea, provided sufficiently potent enzyme inhibition (32 μM) to prompt further analogue work. Acids and acid isosteres were incorporated at the 5-pyridyl position of this fragment, bridging to a key asparagine

  描述和发现了一种新型的结合在ATP域中的细菌拓扑异构酶（DNA促旋酶和拓扑异构酶IV）抑制剂。片段分子1-乙基-3-（2-吡啶基）脲提供了足够强的酶抑制作用（32μM），可促进进一步的类似工作。在该片段的5-吡啶基位置掺入了酸和酸等排体，桥接至关键的天冬酰胺残基，改善了酶抑制作用，并产生了可测量的抗菌活性。由于有利的亲脂性相互作用，在4-吡啶基位置的CF 3-噻唑取代基改善了抑制能力。与革兰氏阳性病原体金黄色葡萄球菌和肺炎链球菌相比，具有良好的抗菌活性和革兰氏阴性病原流感嗜血杆菌和卡他莫拉菌。前体代谢物的掺入和突变分析研究支持双分子拓扑异构酶抑制作用的作用方式，DNA合成的阻断。化合物35在小鼠金黄色葡萄球菌疾病模型中是有效的，其中证明了菌落形成单位相对于对照减少了4.5个对数。
• A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines, and Pharmaceuticals
  作者：J. Luke Koniarczyk、David Hesk、Alix Overgard、Ian W. Davies、Andrew McNally

  DOI：10.1021/jacs.7b11710

  日期：2018.2.14

  molecules are valuable for medicinal chemistry. The prevalence of pyridines and diazines in pharmaceuticals means that new ways to label these heterocycles will present opportunities in drug design and facilitate absorption, distribution, metabolism, and excretion (ADME) studies. A broadly applicable protocol is presented wherein pyridines, diazines, and pharmaceuticals are converted into heterocyclic phosphonium

  将氘和氚原子结合到有机分子中的方法对于药物化学很有价值。药物中吡啶和二嗪的流行意味着标记这些杂环的新方法将为药物设计提供机会，并促进吸收、分布、代谢和排泄 (ADME) 研究。提出了一个广泛适用的协议，其中吡啶、二嗪和药物被转化为杂环鏻盐，然后进行同位素标记。同位素以高产率掺入，并且通常具有独特的区域选择性。
• [EN] DERIVATIVES OF 2-[2-(BENZO- OR PYRIDO-) THIAZOLYLAMINO]-6-AMINOPYRIDINE, USEFUL IN THE TREATMENT OF RESPIRATORIC, ALLERGIC OR INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS DE 2-[2-(BENZO- OU PYRIDO-)THIAZOLYLAMINO]-6- AMINOPYRIDINE, UTILES DANS LE TRAITEMENT DE MALADIES RESPIRATOIRES, ALLERGIQUES OU INFLAMMATOIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2011110575A1

  公开（公告）日：2011-09-15

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular Itk activity.

  本发明涉及某些新型化合物。具体而言，本发明涉及通式（I）的化合物及其盐。本发明的化合物是激酶活性的抑制剂，特别是Itk活性的抑制剂。
• [EN] PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS COMME INHIBITEURS DE LTK
  申请人：GLAXO GROUP LTD

  公开号：WO2010106016A1

  公开（公告）日：2010-09-23

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular ltk activity.

  本发明涉及某些新颖化合物。具体而言，本发明涉及以下公式（I）的化合物及其盐类。发明的化合物是激酶活性的抑制剂，特别是ltk活性的抑制剂。